Novavax (NVAX) to Release Quarterly Earnings on Wednesday

Novavax (NASDAQ:NVAX) is projected to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.67) per share and revenue of $90.93 million for the quarter.

Novavax Stock Performance

Shares of NASDAQ:NVAX opened at $8.25 on Wednesday. The firm has a market capitalization of $1.32 billion, a PE ratio of -3.65, a price-to-earnings-growth ratio of 63.06 and a beta of 2.14. The firm has a fifty day moving average of $8.72 and a 200 day moving average of $10.20. Novavax has a 52-week low of $3.81 and a 52-week high of $23.86.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $19.00 price target on shares of Novavax in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $17.83.

Insider Activity

In other news, Director Rachel K. King sold 4,150 shares of the company’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $9.02, for a total transaction of $37,433.00. Following the completion of the transaction, the director now directly owns 14,770 shares of the company’s stock, valued at approximately $133,225.40. This represents a 21.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director James F. Young sold 4,600 shares of the company’s stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $8.48, for a total transaction of $39,008.00. Following the transaction, the director now directly owns 57,160 shares of the company’s stock, valued at approximately $484,716.80. This trade represents a 7.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,150 shares of company stock valued at $119,641. Insiders own 1.00% of the company’s stock.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.